{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal MSC-NTF cells",
            "NStudiesAvail": 430108,
            "NStudiesFound": 6,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 6,
            "FieldList": [
                  "MaximumAge",
                  "MinimumAge",
                  "NCTId",
                  "NCTIdAlias",
                  "OfficialTitle",
                  "OrgClass",
                  "OrgFullName",
                  "OrgStudyId",
                  "OrgStudyIdDomain",
                  "OrgStudyIdLink",
                  "OrgStudyIdType",
                  "OtherEventAssessmentType",
                  "OtherEventNotes",
                  "OtherEventOrganSystem",
                  "OtherEventSourceVocabulary"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "MaximumAge": [
                              "75 Years"
                        ],
                        "MinimumAge": [
                              "20 Years"
                        ],
                        "NCTId": [
                              "NCT01051882"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase I/II, Open Label Study to Evaluate Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Brainstorm-Cell Therapeutics"
                        ],
                        "OrgStudyId": [
                              "MSC-NTF-001-HMO-CTIL"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 2,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03799718"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn\u00ae [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Brainstorm-Cell Therapeutics"
                        ],
                        "OrgStudyId": [
                              "BCT-101-US"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 3,
                        "MaximumAge": [
                              "75 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02017912"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Brainstorm-Cell Therapeutics"
                        ],
                        "OrgStudyId": [
                              "BCT-001-US"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 4,
                        "MaximumAge": [
                              "60 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03280056"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn\u00ae (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Brainstorm-Cell Therapeutics"
                        ],
                        "OrgStudyId": [
                              "BCT-002-US"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 5,
                        "MaximumAge": [
                              "63 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04681118"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown\u00ae (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Brainstorm-Cell Therapeutics"
                        ],
                        "OrgStudyId": [
                              "BCT-003-US"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 6,
                        "MaximumAge": [
                              "75 Years"
                        ],
                        "MinimumAge": [
                              "20 Years"
                        ],
                        "NCTId": [
                              "NCT01777646"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Brainstorm-Cell Therapeutics"
                        ],
                        "OrgStudyId": [
                              "MSC-NTF-002-HMO-CTIL"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  }
            ]
      }
}